文献速递瘢痕与激光创面修复

整合多组学分析识别瘢痕疙瘩线粒体功能障碍诊断特征、分子亚型及药物重定位候选

Integrative multi-omics analysis identifies a mitochondrial dysfunction-associated diagnostic signature, molecular subtypes, and drug repurposing candidates for keloid disease.
PubMed 文献 · Burns · 2026-06-21

该研究整合五个批量转录组队列(核心训练集46例,独立诊断验证7例瘢痕疙瘩/对照样本)和单细胞RNA-seq数据集(8592个细胞),分析线粒体相关基因在瘢痕疙瘩中的表达。研究识别出648个线粒体相关差异表达基因,构建了七基因转录组特征(RAB3GAP2、NCOA6、NSF、HEBP1、IDS、MSX1、BRWD1),内部测试AUC为0.881,但独立验证集极小(n=7)需谨慎解读。结论为假设生成性框架,临床可操作前需更大队列和功能组织验证。

要点

  • 识别出七基因线粒体相关转录组特征,内部测试AUC 0.881,但独立验证集仅7例。
  • 瘢痕疙瘩相关评分(KAS)在瘢痕疙瘩中高于对照(P=1.27×10⁻⁵),跨队列泛化中等(GSE188952 AUC=0.667)。
  • 单细胞分析显示KAS在树突状细胞中最高,批量免疫相关性经FDR校正后不显著。

核心结论

  • 研究提供了一种假设生成性的线粒体相关转录组框架,用于瘢痕疙瘩诊断和分层,但特征、KAS或药物假设需更大队列和功能组织验证后方可临床转化。

研究设计与样本

  • 整合五个批量转录组队列(核心训练集46例样本;独立诊断验证7例瘢痕疙瘩/对照样本)和一个单细胞RNA-seq数据集(8592个细胞)。
  • 采用差异表达分析、WGCNA、机器学习、NMF聚类、免疫浸润、单细胞评分及基于更严格线粒体能量代谢子集的敏感性分析。

主要发现

  • 识别出648个线粒体相关差异表达基因,下调基因富集于细胞周期和有丝分裂通路,上调基因富集于免疫相关通路。
  • 更严格的线粒体能量代谢子集显示相同主导下调方向(48个显著基因,41个下调)。
  • WGCNA显示ME11为瘢痕疙瘩相关模块(r=0.504,P=3.58×10⁻⁴)。
  • LASSO选择七基因转录组特征(RAB3GAP2、NCOA6、NSF、HEBP1、IDS、MSX1、BRWD1),内部测试AUC 0.881,独立验证集(n=7)AUC 1.000需谨慎解读。
  • 瘢痕疙瘩相关评分(KAS)在瘢痕疙瘩中高于对照(P=1.27×10⁻⁵),但在GSE188952中跨队列泛化中等(AUC=0.667);GSE218007供体均值AUC=0.889但固定KAS性能在外部数据集中异质。

关键数值与推荐

  • 七基因特征内部测试AUC 0.881,独立验证集(n=7)AUC 1.000。
  • KAS在瘢痕疙瘩与对照间差异P=1.27×10⁻⁵;GSE188952中AUC=0.667;GSE218007供体均值AUC=0.889。
  • WGCNA模块ME11与瘢痕疙瘩相关r=0.504,P=3.58×10⁻⁴。

临床怎么用

  • 目前该七基因特征和KAS仅作为研究工具,不能用于临床诊断或分层决策。
  • 药物重定位假设为探索性,需实验验证后方可考虑临床研究。

局限性

  • 独立诊断验证集样本量极小(n=7),AUC 1.000需谨慎解读。
  • KAS跨队列泛化性能中等且异质,批量免疫相关性经FDR校正后不显著。
  • 扰动特征分析仅产生探索性治疗假设,非验证药物候选;需更大队列和功能组织验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Keloid, a fibroproliferative disorder, has limited treatments and lacks reliable biomarkers. Mitochondrial dysfunction is implicated in fibrosis, but its transcriptomic role in keloid remains incompletely characterised. METHODS: We integrated five bulk transcriptomic cohorts (core training set: 46 samples; independent diagnostic validation: 7 keloid/control samples) and a single-cell RNA-seq dataset (8592 cells) to profile mitochondrial-related genes. Differential expression, WGCNA, machine learning, NMF clustering, immune infiltration, single-cell scoring, and sensitivity analyses using a stricter mitochondrial energy-metabolism subset were performed. RESULTS: We identified 648 mitochondrial-related differentially expressed genes, with downregulated genes enriched in cell cycle and mitotic pathways and upregulated genes enriched in immune-related pathways. A stricter mitochondrial energy-metabolism subset showed the same dominant downregulated direction (48 significant genes; 41 downregulated). WGCNA revealed ME11 as the keloid-associated module (r = 0.504, P = 3.58 ×10-4). LASSO selected a seven-gene transcriptomic signature (RAB3GAP2, NCOA6, NSF, HEBP1, IDS, MSX1, BRWD1) achieving AUC 0.881 in internal testing and 1.000 in the very small independent validation set (n = 7), which should be interpreted cautiously. The keloid-associated score (KAS), defined as an unsupervised PC1 score of these genes for stratification rather than as the supervised LASSO probability, was higher in keloid than controls (P = 1.27 × 10⁻⁵) but showed only moderate cross-cohort generalisation in GSE188952 (AUC = 0.667). Additional public GEO mining identified GSE218007 as a supportive sensitivity dataset (donor-mean AUC = 0.889), although fixed KAS performance remained heterogeneous across external datasets. Bulk immune correlations did not remain significant after FDR correction; single-cell KAS was highest in dendritic cells. Perturbation-signature analysis generated exploratory therapeutic hypotheses rather than validated drug candidates. CONCLUSION: This study provides a hypothesis-generating mitochondrial-related transcriptomic framework for keloid diagnosis and stratification. Validation in larger cohorts and functional tissue is required before the signature, KAS, or drug hypotheses are clinically actionable.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Le X, Fan Y, Xu S, et al. Integrative multi-omics analysis identifies a mitochondrial dysfunction-associated diagnostic signature, molecular subtypes, and drug repurposing candidates for keloid disease. Burns. 2026. PMID: 42413388. doi:10.1016/j.burns.2026.108118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。